A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to compare the effect of azacitidine (Vidaza) to conventional care regimens on overall survival in elderly AML patients.
Inclusion Criteria:
Diagnosis of one of the following
Bone marrow blasts >30%
Age ≥ 65 years
Easter Cooperative Oncology Group (ECOG) 0-2
Exclusion Criteria:
Ontario, M5G 2M9, Canada
Jiangsu, 210029, China
Aquitaine, 64109, France
Rostock, Mecklenburg-Vorpommern 18057, Germany
Essen, Nordrhein-Westfallen 45122, Germany
Düesseldorf, North Rhine-Westphalia 40211, Germany
Beer Yaakov, 70300, Israel
Rionero in Vulture, Potenza 85028, Italy
Wroclaw, Lower Silesian Voivodeship 50-367, Poland
Wroclaw, Lower Silesian Voivodeship 53-439, Poland
Katowice, Silesian Voivodeship 40-032, Poland
Lódz, Łódź Voivodeship 93-510, Poland
Nizhny Novgorod, 603126, Russia
Gangnam-gu, Seoul 135-710, South Korea
Jongno-gu, Seoul 110-774, South Korea
Seodaemun-gu, Seoul 120-752, South Korea
Niao-Sung Hsiang, Kaohsiung 83301, Taiwan